Longevity & AgingNext-Gen Atherosclerosis Treatments Target Inflammation at Its Source
A comprehensive review in Cell Reports Medicine argues that atherosclerosis treatment must move beyond LDL reduction toward mechanistically precise, patient-level interventions. The authors examine how technologies including monoclonal antibodies, siRNA, mRNA therapeutics, CRISPR base editing, and epigenetic reprogramming can target inflammation biology within plaques and across organ systems. Critically, they highlight the bone marrow — through clonal hematopoiesis and trained immunity — as an underappreciated systemic driver of cardiovascular risk. The review also covers colchicine trials, IL-1β/IL-6 pathway inhibition, Lp(a)-targeting siRNA, and regulatory T cell therapies, while acknowledging that identifying which patients will benefit remains the central translational challenge.
